Cabaletta Bio (CABA) Free Cash Flow (2018 - 2025)
Cabaletta Bio (CABA) posted quarterly Free Cash Flow of -$35.3 million for Q4 2025, down 50.41% year-over-year from -$71.3 million in Q4 2024, and down 2.54% quarter-over-quarter from -$34.5 million in Q3 2025.
Cabaletta Bio (CABA) Free Cash Flow (2018 - 2025) Analysis & Trends
Cabaletta Bio's Free Cash Flow history runs 8 years deep, the most recent figure standing at -$35.3 million for Q4 2025.
- In Q4 2025, Free Cash Flow fell 50.41% year-over-year to -$35.3 million; the TTM figure through Dec 2025 stood at -$131.1 million (down 44.95% YoY), while the FY2025 annual figure was -$131.1 million, down 44.95% from the prior year.
- Free Cash Flow for Q4 2025 stood at -$35.3 million, down from -$34.5 million in the prior quarter.
- The five-year high for Free Cash Flow was -$7.0 million in Q2 2021, with the low at -$35.3 million in Q4 2025.
- The 5-year median for Free Cash Flow is -$13.0 million (2022), against an average of -$17.9 million.
- The sharpest annual moves came in 2022 and 2024: Free Cash Flow increased 13.88% in 2022, then plunged 95.51% in 2024.
- Cabaletta Bio's Free Cash Flow stood at -$11.6 million in 2021, then rose by 13.88% to -$10.0 million in 2022, then tumbled by 66.58% to -$16.6 million in 2023, then sank by 41.15% to -$23.5 million in 2024, then plunged by 50.41% to -$35.3 million in 2025.
- Business Quant data shows CABA's Free Cash Flow at -$35.3 million in Q4 2025, -$34.5 million in Q3 2025, and -$29.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Cabaletta Bio | 466.25 Mn | 466.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -35.34 Mn |
| Dec 31, 2025 | -35.34 Mn |
| Sep 30, 2025 | -34.47 Mn |
| Sep 30, 2025 | -34.47 Mn |
| Jun 30, 2025 | -29.68 Mn |
| Jun 30, 2025 | -29.68 Mn |
| Mar 31, 2025 | -31.59 Mn |
| Mar 31, 2025 | -31.59 Mn |
| Dec 31, 2024 | -23.50 Mn |
| Dec 31, 2024 | -23.50 Mn |
| Sep 30, 2024 | -20.58 Mn |
| Sep 30, 2024 | -20.58 Mn |
| Jun 30, 2024 | -21.71 Mn |
| Jun 30, 2024 | -21.71 Mn |
| Mar 31, 2024 | -24.65 Mn |
| Mar 31, 2024 | -24.65 Mn |
| Dec 31, 2023 | -16.65 Mn |
| Dec 31, 2023 | -16.65 Mn |
| Sep 30, 2023 | -13.08 Mn |
| Sep 30, 2023 | -13.08 Mn |